Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Multiple Cancer Types

This is an open-label, multi-center, non-randomized, Phase 1b / 2 study to assess the safety and efficacy of fruquintinib in combination with tislelizumab in patients with locally advanced or metastatic solid tumors. This study will be conducted in 2 parts; a Safety Lead-in Phase (Part 1) and a Dose Expansion Phase (Part 2). The Safety Lead-in Phase, open to any-comer solid tumors, will determine the RP2D. The RP2D will be administered to 3 cohorts of patients in the Dose Expansion Phase. - Cohort A: Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IO-treated) - Cohort B: Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IO-Nave) - Cohort C: Advanced or Metastatic Endometrial Cancer (EC) (IO-Nave) - Cohort D: Advanced or Metastatic Colorectal Cancer (mCRC) (IO-Nave)
Miscellaneous, Phase I
Eng, Cathy

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: